Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
RSS

Phase IIb study of eliapixant in refractory chronic cough meets primary efficacy outcome

Aug. 4, 2021

Boehringer Ingelheim advances development of alteplase for COVID-19 ARDS

July 28, 2021

Wuhan LL Science and Technology Development divulges P2X4 receptor antagonists

July 23, 2021

BIX-119 leads to improved clinical benefit through blocking both IL-17 and IL-22

July 19, 2021

Model of steroid-resistant neutrophilic asthma developed to test treatments

July 19, 2021

FDA accepts IND application for phase I/II study of ExoFlo in ARDS

July 16, 2021

Genfit presents prodrugs of nuclear receptor ROR-gamma modulators

July 14, 2021

Amniotics to advance PulmoStem into clinic next year

July 12, 2021

Chiesi Farmaceutici synthesizes new LPAR2 antagonists

July 8, 2021

Phase II trial evaluates CBP-201 for chronic rhinosinusitis with nasal polyps

July 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...